• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

SimonMed Imaging Partners with Lunit to Deploy AI for Breast Cancer Detection

by Jasmine Pennic 04/23/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– SimonMed Imaging, one of the largest and most advanced outpatient medical imaging providers in the United States, announced a significant partnership with Lunit, a global leader in AI-driven cancer diagnostics and therapeutics. 

– The collaboration aims to bring a new era of artificial intelligence (AI)-powered breast cancer detection to patients across SimonMed’s extensive network, marking a major milestone in the company’s mission to save lives through early detection.

Selecting Advanced AI for Personalized Screening

After conducting a thorough evaluation of various AI technologies available on the market, SimonMed has selected Lunit INSIGHT DBT™, used in combination with Volpara Analytics™ (from Volpara Health, now a Lunit company), as its chosen solution. This best-in-class software package will now power SimonMed’s Personalized Breast Cancer Detection (PBCD) service. The PBCD service is specifically designed to offer every patient a highly precise, personalized, and data-driven breast cancer screening experience.

Enhancing Detection Accuracy and Speed Across Network

Lunit INSIGHT DBT is an FDA-cleared AI tool trained on millions of mammography images. It is engineered to identify even the most subtle indicators of breast cancer, thereby improving both the sensitivity (ability to detect cancer) and specificity (ability to rule out cancer) of screenings. Integrating this advanced AI into SimonMed’s national network, which includes over 170 accredited centers and is supported by more than 200 subspecialty-trained radiologists, is expected to facilitate earlier detection, reduce turnaround times for results, and provide more actionable insights for patients and their referring physicians.

“This is more than just an upgrade—it’s an important step forward for our patient’s health,” said Dr. Sean Raj, Chief Innovation Officer at SimonMed Imaging and Fellow of The Society of Breast Imaging (FSBI) “We’ve evaluated a range of AI technologies, and Lunit’s performance, speed, and clinical validation stood above the rest. This partnership enables us to offer the most precise and personalized mammogram experience to date—and when paired with our board-certified breast radiologists, we believe it offers the most advanced mammogram available today”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Breast Cancer

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |